One size does not fit all: Challenging some dogmas and taboos in drug discovery

Christina L L Chai, P. Mátyus

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Advances in genetics, biology, chemical synthesis and computational methods have contributed to the understanding of diseases and drugs and with all of the above, there is an expectation that we are in a better position than ever before to create effective medicines for our needs. The reality is, however, disconnected from the expectation - US FDA drug approval statistics show that the number of approved drugs, especially the first-in-class drugs, is not commensurate with our improved knowledge. In this perspective, we offer our views on the possible reasons for this, focusing on small-molecule drugs and suggest some ideas for further considerations.

Original languageEnglish
Pages (from-to)29-38
Number of pages10
JournalFuture Medicinal Chemistry
Volume8
Issue number1
DOIs
Publication statusPublished - Jan 1 2016

Fingerprint

Taboo
Drug Discovery
Pharmaceutical Preparations
Drug Approval

Keywords

  • high-throughput screening
  • pan assay interference compounds (PAINS)
  • polypharmacology
  • target-based screening
  • toxicophores

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Molecular Medicine

Cite this

One size does not fit all : Challenging some dogmas and taboos in drug discovery. / Chai, Christina L L; Mátyus, P.

In: Future Medicinal Chemistry, Vol. 8, No. 1, 01.01.2016, p. 29-38.

Research output: Contribution to journalArticle

@article{1bc8093d8a024eb783a9c9cc402908d5,
title = "One size does not fit all: Challenging some dogmas and taboos in drug discovery",
abstract = "Advances in genetics, biology, chemical synthesis and computational methods have contributed to the understanding of diseases and drugs and with all of the above, there is an expectation that we are in a better position than ever before to create effective medicines for our needs. The reality is, however, disconnected from the expectation - US FDA drug approval statistics show that the number of approved drugs, especially the first-in-class drugs, is not commensurate with our improved knowledge. In this perspective, we offer our views on the possible reasons for this, focusing on small-molecule drugs and suggest some ideas for further considerations.",
keywords = "high-throughput screening, pan assay interference compounds (PAINS), polypharmacology, target-based screening, toxicophores",
author = "Chai, {Christina L L} and P. M{\'a}tyus",
year = "2016",
month = "1",
day = "1",
doi = "10.4155/fmc.15.167",
language = "English",
volume = "8",
pages = "29--38",
journal = "Future Medicinal Chemistry",
issn = "1756-8919",
publisher = "Future Science",
number = "1",

}

TY - JOUR

T1 - One size does not fit all

T2 - Challenging some dogmas and taboos in drug discovery

AU - Chai, Christina L L

AU - Mátyus, P.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Advances in genetics, biology, chemical synthesis and computational methods have contributed to the understanding of diseases and drugs and with all of the above, there is an expectation that we are in a better position than ever before to create effective medicines for our needs. The reality is, however, disconnected from the expectation - US FDA drug approval statistics show that the number of approved drugs, especially the first-in-class drugs, is not commensurate with our improved knowledge. In this perspective, we offer our views on the possible reasons for this, focusing on small-molecule drugs and suggest some ideas for further considerations.

AB - Advances in genetics, biology, chemical synthesis and computational methods have contributed to the understanding of diseases and drugs and with all of the above, there is an expectation that we are in a better position than ever before to create effective medicines for our needs. The reality is, however, disconnected from the expectation - US FDA drug approval statistics show that the number of approved drugs, especially the first-in-class drugs, is not commensurate with our improved knowledge. In this perspective, we offer our views on the possible reasons for this, focusing on small-molecule drugs and suggest some ideas for further considerations.

KW - high-throughput screening

KW - pan assay interference compounds (PAINS)

KW - polypharmacology

KW - target-based screening

KW - toxicophores

UR - http://www.scopus.com/inward/record.url?scp=84952684676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952684676&partnerID=8YFLogxK

U2 - 10.4155/fmc.15.167

DO - 10.4155/fmc.15.167

M3 - Article

C2 - 26689236

AN - SCOPUS:84952684676

VL - 8

SP - 29

EP - 38

JO - Future Medicinal Chemistry

JF - Future Medicinal Chemistry

SN - 1756-8919

IS - 1

ER -